🔬🩸 Hematology Updates: Myeloma Trials, AML Response Breakthroughs & First-in-Canada Therapies
From next-gen triplet regimens in AML and continuous low-dose myeloma trials to global approvals in PNH and sickle cell advances—this week’s hematology update delivers powerful insights shaping the future of blood cancer and rare disease care.
💡 Key Highlights This Week:
✅ Starton launches Phase 2a STAR-LLD trial in multiple myeloma with promising safety profile
🧬 J&J’s bleximenib + VEN + AZA combo hits 90 percent ORR in newly diagnosed AML
🧪 Syndax’s revumenib shows 48 percent ORR and 63 percent MRD-negativity in NPM1-mutant AML
🧫 Aptose’s tuspetinib triplet achieves 100 percent composite CR rate in mutation-agnostic AML
💊 FDA approves tablet formulation of BRUKINSA for simplified dosing in B-cell malignancies
🚀 Sumitomo’s nuvisertib receives Fast Track status for myelofibrosis with symptom and spleen volume response
🧵 Novartis’ Fabhalta raises hemoglobin by 2.01 g/dL with no transfusions in PNH
🍁 Roche’s PiaSky becomes first monthly subcutaneous PNH therapy approved in Canada
🧬 BEAM-101 exceeds 60 percent HbF and drops HbS below 40 percent in all treated SCD patients
🌱 Vasceptor earns FDA Orphan Drug Designation as transdermal anti-inflammatory for sickle cell disease
🎯Whether you’re tracking advancements in AML response rates, patient-friendly PNH therapies, or gene-editing strategies in sickle cell disease—this week’s update keeps you informed and ahead of the curve.
📢 Stay Ahead in Hematology Research!
✅ Like, share, and subscribe for weekly updates on blood cancers, cell therapies, and rare hematologic breakthroughs.
#Hematology #MultipleMyeloma #AML #PNH #SickleCellDisease #ClinicalTrials #Bleximenib #Revumenib #Fabhalta #Tuspetinib #Nuvisertib #BRUKINSA #BEAM101 #Vasceptor #LucidQuest #PharmaInnovation #BloodDisorders #BiotechNews #OrphanDrugs #HematologyUpdates